glp 1 agonist nash Resmetirom and GLP-1 agonists for MASH: complementary rather than exclusive The Rise of the GLP-1s:
Description
Gewitz, A
in fact, some clinical evidences suggest it may have a potential protective effect in reducing lung cancer risk
doi: 10.1007/s10557-019-06915-8 90 VermaMKGoelRKrishnadasNNemmaniKVS
Indeed, surveys show that as of early 2026, about one in eight U.S
18.Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al
00159-0/asset/a9e0ae75-5aca-406f-86c1-bf873f626e1e/main.assets/gr3_lrg.jpg)
